OSUCCC CUSP2CT

项目总结 俄亥俄州立大学(OSU)将代表性不足的人群与临床试验联系起来的总体目标 (CUSP2CT)是为了增加NCI国家临床试验的种族/少数民族的转介和收益 俄亥俄州立大学综合癌症中心(OSUCCC)的NCTN预防/控制和治疗试验。 这项研究是基于人口健康和健康中心开发的社会生态模型 差异(沃内克等人Am J Public Health 2008)，并利用临床应计理论模型 试验(Paskett等人)临床ADV血液醇Onol 2003)。OSUCCC为该州的集水区提供服务 俄亥俄州是我们95%以上的癌症患者的居住地。与OSUCCC癌症中心密切合作 卫生公平(CCHE)、OSUCCC国家外展网络、社区伙伴组织、社区 OSUCCC转诊区域的提供者，James医院网络站点，NCI社区肿瘤学研究 计划(NCORP)在俄亥俄州的站点和OSUCCC临床试验办公室，我们的目标将通过 完成以下具体目标：1)对转介模式和应计费用进行基线评估 种族和少数民族参加OSUCCC癌症疾病组的临床试验(乳腺癌、胃肠道疾病、 泌尿生殖科、胸科、血液科和其他)，并在系统中检查因素(即，合格的临床试验 方案、临床背景和文化)、提供者(与患者讨论试验)和患者级别(同意或拒绝 参与)影响转介和累算(第一阶段)；2)在一个步骤中实施多层次干预 楔形设计在9个少数民族癌症高发县转诊实践中的应用 使用应计到临床试验框架的集水区(Paskett等人)。Clin Adv hematol Onol 2003)，in 第二阶段.干预措施将包括一个面向社区成员和社区的外联部分 实践，以及涉及患者、提供者和医院系统的可及部分(在两个转诊 中心和OSUCCC)直接解决第一阶段中发现的问题；以及3)评估影响 第三至第四阶段对转诊(主要结果)和应计模式(次要结果)的干预情况 临床试验。将采用定性和定量相结合的方法。传播我们的主要研究结果 多层次的干预是该项目的高度优先事项。

PROJECT SUMMARY The overall goal of The Ohio State University (OSU) Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) is to increase the referral and accrual of racial/ethnic minorities to NCI's National Clinical Trials Network (NCTN) prevention/control and treatment trials at the OSU Comprehensive Cancer Center (OSUCCC). This research is grounded in the socioecologic model developed by the Centers for Population Health and Health Disparities (Warnecke, et al. Am J Public Health 2008) and utilizes the theoretical model, Accrual to Clinical Trials (Paskett, et al. Clin Adv Hematol Oncol 2003). The OSUCCC serves the catchment area of the state of Ohio where over 95% of our patients with cancer reside. Working closely with the OSUCCC Center for Cancer Health Equity (CCHE), OSUCCC National Outreach Network, community partner organizations, community providers in the OSUCCC referral area, James Hospital Network sites, NCI Community Oncology Research Program (NCORP) sites in Ohio, and the OSUCCC Clinical Trials Office, our goal will be accomplished by completing the following specific aims: 1) Conduct a baseline assessment of referral patterns and accrual of racial and ethnic minorities to clinical trials at OSUCCC by cancer disease group (breast, gastrointestinal, genitourinary, thoracic, hematologic, and others) and examine factors at the system (i.e., eligible clinical trial protocol, clinic context and culture), provider (trial discussed with patient), and patient level (agreed or refused participation) that influence referral and accrual (Phase I); 2) Implement a multi-level intervention in a stepped wedge design in referring practices in 9 counties with high counts of minority cancer cases in the OSUCCC catchment area using the Accrual to Clinical Trials framework (Paskett, et al. Clin Adv Hematol Oncol 2003), in Phase II. The intervention will include an outreach component, directed at community members and community practices, and an in-reach component, involving patients, providers, and the hospital system (at both referral centers and the OSUCCC) that directly addresses problems identified in Phase I; and 3) to evaluate the impact of the intervention on referral (primary outcome) and accrual patterns (secondary outcomes) in Phase III to clinical trials. Both qualitative and quantitative methods will be used. Dissemination of the key findings of our multi-level intervention is a high priority of this project.